Gitnux/Report 2026

Sleep Aid Industry Statistics

The global sleep aids market is estimated at $53.0 billion in 2026, explore the figures behind growth, companies, and trends across medications and devices.
26Statistics
26Sources
4Sections
1Visuals
15mRead
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 37 days

01 Industry overview

The sleep aid industry at a glance

The global sleep aids market is estimated at $53.0 billion in 2026, with demand supported by widespread sleep-aid use, insomnia prevalence and expanding prescription, OTC, supplement and device categories.

$53.0B[2]
Global market size, 2026
8.7%[2]
Forecast CAGR, 2026–2033
36.4%[2]
North America share, 2025
12.9%[9]
U.S. adults using sleep aids, 2024
Market size
Grand View Research estimates the global sleep aids market at $49.1 billion in 2025 and $53.0 billion in 2026. Estimates vary by market definition: Emergen Research puts the 2025 market at $15.50 billion, reflecting a narrower scope of products and channels.[2][3]
Forecast & CAGR
The Grand View Research forecast rises from $53.0 billion in 2026 to $95.2 billion in 2033, equivalent to an 8.7% CAGR. Emergen Research projects a 6.0% CAGR from 2026 to 2035, reaching $27.76 billion, illustrating the effect of differing industry definitions.[2][3]
Market share & regions
North America held 36.4% of global sleep-aid revenue in 2025 according to Grand View Research. Emergen Research reports a higher 42.6% North American share for its narrower market definition in the same year.[2][3]
Segmentation
Grand View Research identifies medications as the largest product category, with 36.4% of revenue in 2025, while insomnia represented 32.5% by disorder. Emergen Research reports dietary supplements as its leading product segment at 44.0%, insomnia at 83.0% by disorder and retail pharmacies at 48.0% by distribution channel.[2][3]
Trends, drivers & challenges
Market growth is being driven by sleep disorders, insomnia, sleep apnea, consumer interest in supplements and adoption of newer orexin-targeting medicines. Challenges include uncertain long-term evidence for some supplements, variable supplement dose and purity, and safety concerns associated with long-term OTC sleep-aid use.[2][10][11]
Consumer behavior & competition
In the United States, 12.9% of adults used any sleep aid most days or every day during the past 30 days in 2024; 5.2% used prescription medication and 5.7% used OTC medication or supplements. Usage was higher among women at 14.8% than men at 10.8%, and higher among adults aged 65 and older at 15.8%.[9]
M&A
M&A activity in 2026 has focused on sleep-wake medicines and sleep-related devices. Eli Lilly completed its acquisition of Centessa Pharmaceuticals in June 2026 to expand its neuroscience and sleep-wake pipeline, while ResMed acquired Noctrix Health for $340 million in June 2026.[12][13]
Regulation
In the United States, OTC nighttime sleep-aid drug products are governed by 21 CFR Part 338, which sets conditions for products to be generally recognized as safe and effective. NIH states that dietary supplements such as melatonin are not regulated by the FDA in the same way as medicines and are not reviewed for safety and effectiveness before sale.[11][10]
Latest news
The FDA approved Takeda’s Orzeyful in August 2026 as the first medicine targeting the underlying biology of narcolepsy type 1 and treating its full symptom range. Separately, Lilly completed its acquisition of Centessa in June 2026, adding clinical-stage sleep-wake programs to its neuroscience portfolio.[14][12]

02 Ranking

Top 10 Companies in the Sleep Aid Industry

The leading companies in the sleep aid industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 22, 2026 · Next review December 22, 2026

Verdict

Procter & Gamble stands out for OTC sleep-aid and melatonin supplement coverage because its ZzzQuil portfolio includes medicinal OTC sleep aids and PURE Zzzs melatonin supplements, while Somnigroup International focuses on sleep-product brands since it serves consumers through Tempur-Sealy, Mattress Firm and Dreams.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in sleep-aid medications

    Procter & Gamble

    US

    Ranked #1 · 9.1 · Sleep-aid medications

    Why we picked it: Its OTC sleep-aid and melatonin supplement portfolio spans medicinal products and PURE Zzzs supplements.

  2. Leader in sleep product

    Somnigroup International

    US

    Ranked #2 · 9.0 · Sleep product brands

    Why we picked it: Sleep products are delivered through owned consumer brands, with 51.6% revenue growth and a 10% operating margin.

  3. Leader in sleep-therapy devices

    ResMed

    US

    Ranked #3 · 9.0 · Sleep-therapy devices

    Why we picked it: Its reported $4.5 billion 2025 sleep-and-breathing device revenue anchors its sleep-aid exposure.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the sleep aid industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Procter & Gamble

Sleep-aid medications · US

9.1
2

Somnigroup International

Sleep product brands · US

9.0
3

ResMed

Sleep-therapy devices · US

9.0
4

Fisher & Paykel Healthcare

Sleep-therapy devices · NZ

9.0
5

Oura Health

Sleep-tracking wearables · FI

9.0
6

Sanofi

OTC sleep aids and melatonin products · FR

8.9
7

GSK

Consumer health and pharmaceutical sleep products · GB

8.8
8

Merck

Pharmaceutical and sleep-health products · US

8.7
9

Pfizer

Pharmaceutical and consumer sleep products · US

8.6
10

Serta Simmons Bedding

Mattresses and bedding products · US

8.1

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 22, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 22). Top 10 companies in the sleep aid industry. In Sleep Aid Industry Statistics. Gitnux. https://gitnux.org/sleep-aid-industry-statistics/#top-companies

report visual · Projection

U.S. Sleep/Calm category retail sales

U.S. Sleep/Calm category retail sales grew from $610.0M in 2019 to $975.0M in 2022.

$610M
Start
+16.92%
CAGR · 3y
$975M
Projected
20192022
source-verifiedchpa.org2022

04 Statistics

Market Intelligence

Spain’s market shows 12-month scale using IQVIA shipments, while global values differ by market definition (Grand View Research versus Emergen Research).

Market size, volume and shipments in the sleep aid industry

  • USD 123.5 million was Spain’s sleep-aid market revenue during the 12 months ending May 2025, covering pharmacy sleep-aid products; IQVIA reports sales value.[1]
  • 13.4 million units were sold in Spain during the 12 months ending May 2025, covering pharmacy sleep-aid products; IQVIA reports physical shipments.[1]
  • USD 49.1 billion was the global 2025 sleep-aids market, covering medications and sleep-therapy devices; Grand View Research reports revenue value.[2]
  • USD 15.50 billion was the global 2025 sleep-aids market, covering dietary supplements, prescription medications, OTC medications and other products; Emergen Research reports revenue value.[3]

Forecast growth and shipments in the sleep aid industry

  • USD 95.2 billion is the projected global sleep-aids market value for 2033; Grand View Research covers medications and sleep-therapy devices.[2]
  • 8.7% is the projected compound annual growth rate for the global sleep-aids market from 2026 through 2033; Grand View Research covers medications and sleep-therapy devices.[2]
  • 6.0% is the projected compound annual growth rate for the global sleep-aids market from 2026 through 2035; Emergen Research covers supplements and prescription and OTC medications.[3]
  • USD 27.76 billion is the projected global sleep-aids market value for 2035; Emergen Research covers dietary supplements, prescription medications, OTC medications and other products.[3]

Regional split of the sleep aid industry

  • 13.4 million sleep-aid units were sold in Spain during the 12 months ending May 2025, representing the country’s pharmacy-channel physical volume; IQVIA reports shipment volume.[1]
  • 36.4% of global sleep-aids revenue came from North America in 2025; Grand View Research defines the category as medications and sleep-therapy devices.[2]
  • 42.6% of global sleep-aids revenue came from North America in 2025; Emergen Research defines the category as supplements and prescription and OTC medications.[3]

05 Statistics

People & Workforce

U.S. pharmaceutical manufacturing labor is quantified by NAICS 3254 headcount and wage levels, supporting capacity and cost comparisons.

Employment and hiring in the sleep aid industry

  • 352,200 employees worked in U.S. pharmaceutical and medicine manufacturing (NAICS 3254), the parent manufacturing category containing sleep-aid products, in June 2025.[4]
  • 239,300 production and nonsupervisory employees worked in U.S. pharmaceutical and medicine manufacturing (NAICS 3254) in October 2026.[4]
  • 19,000 additional jobs are projected for U.S. pharmaceutical and medicine manufacturing from 2024 to 2034, increasing employment from 350,500 to 369,500.[4]

Wages and labour costs in the sleep aid industry

  • $41.58 was the average hourly wage in U.S. pharmaceutical and medicine manufacturing in September 2025.[4]
  • $1,629.94 was the average weekly wage in U.S. pharmaceutical and medicine manufacturing in September 2025.[4]
  • $68,290 was the 2024 median annual wage for U.S. pharmaceutical and medicine manufacturing workers, with employment projected at 350,500 in 2024 and 369,500 in 2034.[4]

06 Statistics

Customers & Channel

Retail pharmacies account for 46.7% of U.S. sleeping-aid revenue in 2025 and 48.0% of global sleep-aids revenue, with online pharmacies noted as fastest-growing.

Distribution channels for sleep aid

  • 42.6% of global insomnia-supplement market revenue came through retail pharmacies in 2024; online pharmacies were identified as the fastest-growing channel.[2]
  • 46.7% of U.S. sleeping-aid market revenue came through retail pharmacies in 2025; the category covers prescription, over-the-counter and supplement products.[3]
  • 48.0% of global sleep-aids market revenue came through retail pharmacies in 2025; the category includes medications, supplements and sleep-therapy devices.[3]

07 Statistics

Regulation & Risk

Recent recalls and withdrawals highlight dosing instruction, category eligibility, stability, and potency issues, alongside U.S. and dietary supplement regulation differences.

Recalls and safety notices for sleep aid

  • 1 national recall covered six lots of Life Brand Timed Release Melatonin 10mg tablets in Canada in 2025 because of incorrect dosing instructions; Health Canada classified it as Type II.[5]
  • 1 product withdrawal covered Fallani Sleep & Relax Melatonin Gummy Bears sold in UK TK Maxx and Homesense stores in 2024 because melatonin was not permitted in the product category.[6]
  • 1 Class 2 medicines recall covered 10 expiry-valid batches of KidNaps Melatonin 1mg/ml oral solution in the United Kingdom in 2026 after out-of-specification stability results.[7]

Counterfeiting and grey-market supply of sleep aid

  • One tested imported melatonin sleep aid contained more than 400% of its labelled melatonin amount, according to Australia’s TGA laboratory testing.[8]
  • 18 imported melatonin sleep-aid products were laboratory-tested at Australia’s border between 22 January and 9 September 2025 after suspicion of substandard or falsified goods.[8]
  • More than 900,000 unlawfully imported therapeutic-goods units were seized in Australia during Operation Pangea XVIII in 2025; melatonin products formed a high proportion of the seizures.[8]

Key questions about the sleep aid industry

What is the size of the global sleep-aids market in 2026?
The global sleep-aids market is estimated at $53.0 billion in 2026, based on Grand View Research.
How fast is the sleep-aids market growing from 2026?
Grand View Research projects the market rising from $53.0 billion in 2026 to $95.2 billion in 2033, an 8.7% CAGR. Emergen Research projects a 6.0% CAGR from 2026 to 2035.
Which companies lead the sleep aid industry?
Procter & Gamble stands out for OTC sleep-aid and melatonin supplement coverage because its ZzzQuil portfolio includes medicinal OTC sleep aids and PURE Zzzs melatonin supplements, while Somnigroup International focuses on sleep-product brands since it serves consumers through Tempur-Sealy, Mattress Firm and Dreams.
What technology shift is showing up in sleep-aid product development?
Orexin-targeting medicines are expanding the prescription frontier, and sleep-wake medicines and sleep-related devices are seeing M&A focus in 2026.
How does market structure show up across channels and categories?
In 2025, 46.7% of U.S. sleeping-aid market revenue came through retail pharmacies, covering prescription, over-the-counter and supplement products. In 2025, 48.0% of global sleep-aids market revenue came through retail pharmacies.
What regulatory and quality risks affect sleep-aid products?
In the U.S., OTC nighttime sleep-aid drugs are governed by 21 CFR Part 338 for being generally recognized as safe and effective. NIH states dietary supplements such as melatonin are not reviewed for safety and effectiveness before sale, and melatonin quality issues have triggered recalls and withdrawals.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 22). Sleep Aid Industry Statistics. Gitnux. https://gitnux.org/sleep-aid-industry-statistics
MLA
Samuel Norberg. "Sleep Aid Industry Statistics." Gitnux, 22 Nov 2026, https://gitnux.org/sleep-aid-industry-statistics.
Chicago
Samuel Norberg. 2026. "Sleep Aid Industry Statistics." Gitnux. https://gitnux.org/sleep-aid-industry-statistics.